In the early preclinical studies by Hsi et al., HuLuc63-mediated lysis of myeloma cell lines in cultures with PBMC or in SCID mice was significantly impaired by blocking CD16 with antibodies, using an Fc mutant form of HuLuc63 with reduced CD16 binding capacity, or depleting NK cells (18). The gene discussed is FCGR3A; the disease is plasma cell myeloma.